Amneal Pharmaceuticals AMRX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Amneal Pharmaceuticals (AMRX) Business Model and Operations Summary
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Key Insights
Amneal Pharmaceuticals (AMRX) Core Market Data and Business Metrics
Latest Closing Price
$8.17Market Cap
$2.56 BillionPrice-Earnings Ratio
-21.50Total Outstanding Shares
313.38 Million SharesTotal Employees
8,100Dividend
No dividendIPO Date
May 7, 2018SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQ
Historical Stock Splits
If you bought 25 shares of AMRX before August 26, 2013, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| August 26, 2013 | 1-for-25 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 2,216,417 Shares | 1.44 | 3/14/2025 | 3,196,227 Shares |
| 1,916,831 Shares | 1.44 | 2/28/2025 | 2,763,581 Shares |
| 1,071,904 Shares | 2.45 | 2/14/2025 | 2,621,816 Shares |
| 1,194,553 Shares | 2.03 | 1/31/2025 | 2,421,354 Shares |
| 1,082,135 Shares | 2.72 | 1/15/2025 | 2,947,737 Shares |
| 1,030,886 Shares | 3.2 | 12/31/2024 | 3,299,509 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $295.10 Million |
| Net Cash Flow From Financing Activities, Continuing | $-211.79 Million |
| Net Cash Flow, Continuing | $20.31 Million |
| Net Cash Flow From Financing Activities | $-211.79 Million |
| Net Cash Flow From Investing Activities, Continuing | $-63.00 Million |
| Net Cash Flow From Investing Activities | $-63.00 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Nonoperating Income/Loss | $-304.34 Million |
| Income/Loss From Continuing Operations Before Tax | $-55.01 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Costs And Expenses | $2.85 Billion |
| Research and Development | $190.71 Million |
| Diluted Earnings Per Share | $-0.38 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $-33.16 Million |
| Comprehensive Income/Loss | $-150.05 Million |
| Comprehensive Income/Loss Attributable To Parent | $-150.05 Million |
| Other Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-76.17 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $1.13 Billion |
| Equity Attributable To Noncontrolling Interest | $-245,000 |
| Intangible Assets | $732.38 Million |
| Long-term Debt | $2.39 Billion |
| Other Non-current Liabilities | $30.21 Million |
| Temporary Equity | $64.97 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||